WuXi AppTec and WuXi Biologics are planning to sell some of their operations after the Chinese biotech companies were targeted by the U.S. on national security grounds, the Financial Times reported on Thursday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
